Predictors of early treatment discontinuation in a cohort of patients treated with boceprevir-based therapy for hepatitis C infection.
Predictors of early treatment discontinuation in a cohort of patients treated with boceprevir-based therapy for hepatitis C infection.
复制标题
在接受基于波普瑞韦的丙型肝炎感染治疗的患者队列中，早期治疗终止的预测因素。
DOI：
10.1111/jvh.12201
复制
发表时间：
2014
影响因子：
2.5
通讯作者：
Talwani,R
中科院分区：
文献类型：
--
作者：
Majid,A;McAninch,J;Morgan,DJ;ElKamary,SS;Zhan,M;Kapelusznik,L;Talwani,R
In this real‐world cohort, 49% of patients stopped boceprevir‐based hepatitis C therapy early, with only 20% stopping due to treatment futility. Having more comorbidities was significantly associated with early discontinuation. Tolerability of boceprevir‐based regimens may be substantially worse than reported in clinical trials, particularly for patients with comorbidities.
